primary immunodeficiency diseases article

Upload: nichiichaii

Post on 14-Apr-2018

220 views

Category:

Documents


0 download

TRANSCRIPT

  • 7/30/2019 Primary Immunodeficiency Diseases Article

    1/2

    Primary immunodeficiency diseases: past, present and

    future

    Fuleihan, Ramsaya; Etzioni, Amosb

    More than 180 primary immunodeficiency diseases (PIDs) have been described over the past 60years and improved therapeutic options have become available with safe and effective

    immunoglobulin replacement products, enzyme replacement therapy specifically for adenosine

    deaminase deficiency, improved protocols for stem cell transplantation using bone marrow,peripheral blood or cord blood as well as the development of gene therapy for several of the

    PIDs. However, the cellular, molecular and genetic causes of many PIDs remain to be

    determined.

    This issue ofCurrent Opinion in Allergy and Clinical Immunology is devoted to primaryimmunodeficiency diseases and includes reviews of recent progress in the field, the history of

    how these advances were possible and newer technology that will help uncover the genetic

    causes of PIDs in the near future.

    Ochs and Hitzig (pp. 577587) review the progress in our understanding of PIDs since the first

    report on agammaglobulinemia in 1952 as well as the preceding advances in modern medicine

    that allowed the discovery of PIDs and the development of modern therapeutic options to treat

    them.

    A critical issue in the diagnosis of PIDs is a high

    degree

    of suspicion on the part of the primary care physician. Twenty years ago, the Jeffrey Modell

    Foundation published 10 warning signs to aid physicians in suspecting PIDs and initiating anevaluation. O'Sullivan and Cant (pp. 588594) review recent reports that evaluate the validity of

    the 10 warning signs and propose warning signs targeted to different physician groups in order to

    improve their sensitivity and specificity.

    Common variable immunodeficiency (CVID) is the most common symptomaticimmunodeficiency, yet the pathogenesis of most cases on CVID remains unknown. In this issue,

    Resnick and Cunningham-Rundles (pp. 595601) review the recent advances in identifying the

    genetic causes of CVID including results from genome-wide association

    studies, recent clinical findings from cohort studies and the implications for the treatment of CVID.

    IgA deficiency is the most common immunodeficiency although frequently asymptomatic, but its

    genetic cause remains unknown. Wang and Hammarstrom (pp. 602608) review the recent

    advances in our understanding of IgA deficiency, the association with autoimmunity as well asthe correlation with genes within and outside the MHC region.

  • 7/30/2019 Primary Immunodeficiency Diseases Article

    2/2

    Apoptosis plays an important role in immune homeostasis, and defects in apoptotic pathways

    have been identified in patients with lymphoproliferation and autoimmune disease. In this issue,

    Fleisher and Oliveira (pp. 609615) review the recent discoveries of the genetic causes ofdefective apoptosis and describe the common and distinguishing clinical features and laboratory

    findings in each of these entities.

    The pathogenesis of chronic mucocutaneous candidiasis had remained a mystery even after

    discovering the genetic defects inAIREin autoimmune polyendocrinopathy syndrome type I.Identification of the role of IL-17 in immunity to fungal disease has led to the discovery of the

    pathogenesis of chronic mucocutaneous candidiasis in different PIDs as reviewed in this issue by

    Puel, Casanova and colleagues (pp. 616622).

    Many of the genetic causes of PIDs were discovered using classical methods such as positionalcloning or candidate gene sequencing. Recent advances in DNA sequencing technology have

    allowed whole-genome and whole-exome sequencing at more affordable costs. The application

    of this technology to identify the gene defects in PIDs is reviewed by Chou, Ohsumi and Geha

    (pp. 623628). The authors describe the strengths and limitations of this technology includingthe need for functional studies to confirm the role of affected genes in PIDs.

    Investigation of PIDs has taught us about the development and function of the immune system,

    and the rapid progress in cellular and molecular biology is allowing us to uncover the causes andpathogenesis of many of the PIDs.